Pharm Control Ltd. (fka PMCL)

[PhillyPA65]

iBox Updated - New "Old" PRs Found

Looks likes "they" used the "Pump and Dump" playbook for an inactive Pink Sheet shell. OSC needs to disgorge, fine and ban these people from the securities market.

Source: http://www.hotstockmarket.com/forums/penny-stocks-stock-picks/50199-pmcl-new-reliable-transfer-agent.html


March 22, 2007: Pharm Control Ltd - Victim of Short Selling (M2 PRESSWIRE via COMTEX)

Pharm Control Ltd. (Other OTC: PMCL.PK) management is in the process of ordering a current Non Objecting Beneficial Owners list (NOBO list) from ADP Investor Communications. This is in response to the various emailssent and calls made to the Company's offices concerning possible short selling of the Company's stock.

The NOBO list shows a more complete and comprehensive shareholder profile than is typically available on a shareholder list provided by a transfer agent. In addition, management will order Depository Trust

Corporation (DTC) reports for further examination. Both lists will be utilized to uncover possible short positions.

The NOBO list will be used to determine the naked short position in Pharm Control's common stock. The NOBO list will be compared to the reports from the DTC which contains data regarding all brokers and amounts of shares being held for investors. These lists will be used to get a total amount of shares owned by all shareholders and any naked short positions. The findings will then be reported to the NASD (National Association of Securities Dealers) to take action against the violators of the naked short regulations.

The company will take all necessary action to protect the value of shareholder investments and the steps now being taken exhibit the Company's response to the various emails send and calls made to our offices by investors.

CONTACT: Eugene Kron, Vice President, Pharm Control Ltd. Tel: [phone] e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at

http://www.presswire.net on the world wide web. Inquiries to [e-mail].


April 5, 2007: Pharm Control Ltd Shareholder Update (M2 PRESSWIRE via COMTEX)

Pharm Control Ltd is announcing its plan to change the Company's name to Natural Medications Inc. The new Corporate name is a better reflection of the Company's mandate of researching and developing non-synthetic medicines.

Management also wishes to advise its shareholders that all existing shares will be exchanged on a one existing share for one new share basis (1 for 1) once the Name Change has been confirmed and the new

CUSIP number has been obtained.

It is management's hope that these initiatives taken will combat the recent short selling of the Company's shares.

CONTACT: Eugene Kron, Vice President, Pharm Control Ltd. Tel: [phone] e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].


May 4, 2007: Pharm Control Announces Formation of New Marketing and Distribution Unit (M2 PRESSWIRE via COMTEX)

Pharm Control Ltd is pleased to announce that after discussions with European investment bankers, the Company has decided to form a new corporation called Natural Medicines AG, which will serve as the Company's marketing and distribution arm of in Europe.

The Company intends to spin off by way of stock dividend ownership of this new entity to its shareholders. This will be done after the Company makes the necessary arrangements to list this company on a European stock exchange in the coming months.

Further information including dividend dates will be forthcoming.

CONTACT: Eugene Kron, Vice President, Pharm Control Ltd. Tel: [phone] e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].